The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Community Infections Caused by Extended-Spectrum β-Lactamase–Producing Escherichia coli
Abstract
BACKGROUND: Extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli is an increasingly important group of community pathogens worldwide. These organisms are frequently resistant to many of the antimicrobial agents usually recommended for the treatment of infections caused by E coli, such as penicillins, cephalosporins, fluoroquinolones, and trimethoprim-sulfamethoxazole. Data concerning risk factors, clinical features, and therapeutic options for such infections are scarce. METHODS: A case-control study was performed to investigate the risk factors for all types of community-acquired infections caused by ESBL-producing E coli in 11 Spanish hospitals from February 2002 to May 2003. Controls were randomly chosen from among outpatients with a clinical sample not yielding ESBL-producing E coli. The clinical features of these infections were investigated in the case patients. The efficacy of fosfomycin tromethamine and amoxicillin-clavulanate potassium was observationally studied in patients with cystitis. RESULTS: A total of 122 cases were included. Risk factors selected by multivariate analysis included the following: age older than 60 years; female sex; diabetes mellitus; recurrent urinary tract infections (UTIs); previous invasive procedures of the urinary tract; follow-up in outpatient clinic; and previous receipt of aminopenicillins, cephalosporins, and fluoroquinolones. Urinary tract infections accounted for 93% of the cases; 6% of the patients were bacteremic and 10% needed hospitalization. The cure rate of patients with cystitis was 93% with fosfomycin therapy (all isolates were susceptible); among patients treated with amoxicillin-clavulanate, cure rates were 93% for those with susceptible isolates (minimum inhibitory concentration < or =8 microg/mL) and 56% for those with intermediate or resistant isolates (minimum inhibitory concentration > or =16 microg/mL) (P = .02). CONCLUSIONS: In predisposed patients, ESBL-producing E coli is a notable cause of community-acquired infection, and particularly UTI. Fosfomycin and amoxicillin-clavulanate appear to be effective for cystitis caused by susceptible isolates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Extended-Spectrum β-Lactamases: a Clinical Update
Paterson, D. L., & Bonomo, R. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.4.657-686.2005 · Cited by 3,491
Friedman, N. D., Kaye, K. S., Stout, J. E., McGarry, S. A., Trivette, S. L., Briggs, J. P., Lamm, W., Clark, C., MacFarquhar, J., Walton, A. L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-10-200211190-00007 · Cited by 1,668
(2016) · Pediatric Care Online · doi:10.1542/aap.ppcqr.396241 · Cited by 999
CTX-M: changing the face of ESBLs in Europe
Livermore, D. M., Canton, R., Gniadkowski, M., Nordmann, P., Rossolini, G. M., Arlet, G., Ayala, J., Coque, T. M., Kern-Zdanowicz, I., Luzzaro, F., et al. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl483 · Cited by 927
Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community
Pitout, J. D. D., Nordmann, P., Laupland, K. B., & Poirel, L. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki166 · Cited by 790
Multivariable Analysis: A Practical Guide for Clinicians
Katz, M. H. (1999) · Cited by 479
Rodríguez-Baño, J., Navarro, M. D., Romero, L., Martínez-Martínez, L., Muniain, M. A., Perea, E. J., Pérez-Cano, R., & Pascual, A. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.3.1089-1094.2004 · Cited by 456
Self-citationColodner, R., Rock, W., Chazan, B., Keller, N., Guy, N., Sakran, W., & Raz, R. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-003-1084-2 · Cited by 364
Influx of Extended-Spectrum -Lactamase--Producing Enterobacteriaceae into the Hospital
Ben-Ami, R., Schwaber, M. J., Navon-Venezia, S., Schwartz, D., Giladi, M., Chmelnitsky, I., Leavitt, A., & Carmeli, Y. (2006) · Clinical Infectious Diseases · doi:10.1086/500936 · Cited by 317
Calbo, E., Romaní, V., Xercavins, M., Gómez, L., Vidal, C. G., Quintana, S., Vila, J., & Garau, J. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl035 · Cited by 305
Rodriguez-Bano, J., Navarro, M. D., Romero, L., Muniain, M. A., Cueto, M. D., Rios, M. J., Hernandez, J. R., & Pascual, A. (2006) · Clinical Infectious Diseases · doi:10.1086/508877 · Cited by 279
Self-citationCTX-M: changing the face of ESBLs in the UK
Livermore, D. M., & Hawkey, P. M. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki239 · Cited by 278
Harris, A. D., Karchmer, T. B., Carmeli, Y., & Samore, M. H. (2001) · Clinical Infectious Diseases · doi:10.1086/319600 · Cited by 262
Pitout, J. D. D., Hanson, N. D., Church, D. L., & Laupland, K. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421094 · Cited by 192
Hooton, T. M., Scholes, D., Gupta, K., Stapleton, A. E., Roberts, P. L., & Stamm, W. E. (2005) · JAMA · doi:10.1001/jama.293.8.949 · Cited by 185
Paterson, D. L., Rossi, F., Baquero, F., Hsueh, P.-R., Woods, G. L., Satishchandran, V., Snyder, T. A., Harvey, C. M., Teppler, H., DiNubile, M. J., et al. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki117 · Cited by 184
Predictors of urinary tract infection after menopause: A prospective study
Jackson, S. L., Boyko, E. J., Scholes, D., Abraham, L., Gupta, K., & Fihn, S. D. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.07.045 · Cited by 167
Hernández, J. R., Martínez-Martínez, L., Cantón, R., Coque, T. M., & Pascual, A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.5.2122-2125.2005 · Cited by 163
Self-citationRisk Factors for Urinary Tract Infections in Postmenopausal Women
Hu, K. K., Boyko, E. J., Scholes, D., Normand, E., Chen, C.-L., Grafton, J., & Fihn, S. D. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.9.989 · Cited by 159
Sorlózano, A., Fernández, J. G., Castillo, J. D. D. L.-D., Pino, M. J. S., & Angulo, G. P. (2006) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2005.08.018 · Cited by 59
Community-acquired Extended-Spectrum β-Lactamase Producers, United States
Doi, Y., Adams, J. M., O’Keefe, A., Qureshi, Z. A., Ewan, L., & Paterson, D. L. (2007) · Emerging infectious diseases · doi:10.3201/eid1307.070094 · Cited by 50
Cited by
Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., Moran, G. J., Nicolle, L. E., Raz, R., Schaeffer, A. J., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq257 · Cited by 3,038
Combating Antimicrobial Resistance: Policy Recommendations to Save Lives
Infectious Diseases Society of America (IDSA) (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir153 · Cited by 733
Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain
Rogers, B. A., Sidjabat, H. E., & Paterson, D. L. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq415 · Cited by 716
Rodríguez-Baño, J., Gutiérrez-Gutiérrez, B., Machuca, I., & Pascual, A. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00079-17 · Cited by 704
Self-citationFalagas, M. E., Kastoris, A. C., Kapaskelis, A. M., & Karageorgopoulos, D. E. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70325-1 · Cited by 487
Metadata
- Authors
- Rodríguez-Baño, J., Alcalá, J. C., Cisneros, J. M., Grill, F., Oliver, A., Horcajada, J. P., Tórtola, T., Mirelis, B., Navarro, G., Cuenca, M., Esteve, M., Peña, C., Llanos, A. C., Cantón, R., & Pascual, A.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2008-09-22
- Volume
- 168
- Issue
- 17
- Pages
- 1897
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W1964074354
- Cited by
- 379
- References
- 22
- FWCI
- 13.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.